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• Disease restricted auto-antibody signatures can potentially inform disease 
pathophysiology 
 
• Liver-infiltrating antibody-secreting B cells (ASCs) are reduced in PSC compared to 
PBC 
 
• Cultured liver-infiltrating ASCs in PSC and PBC produce auto-antibodies 
 
• Liver-infiltrating ASCs in PBC secrete auto-antibodies to HK1 and PDC-E2 
 
• Auto-antibodies from liver-infiltrating ASCs in PSC share reactivity to novel antigen 
targets 
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Abstract 
 
Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are immune-
mediated biliary diseases that demonstrate prominent and restricted genetic association with 
human leukocyte antigen (HLA) alleles. In PBC, anti-mitochondrial antibodies (AMA) are 
specific and used as diagnostic biomarkers. PSC-relevant auto-antibodies remain controversial 
despite a distinct HLA association that mirrors archetypical auto-antigen driven disorders. Herein, 
we compared antibody-secreting B cells (ASCs) in PSC and PBC liver explants to determine if 
liver-infiltrating ASCs represent an opportune and novel source of disease-relevant auto-
antibodies. Using enzymatic digestion and mechanical disruption, liver mononuclear cells 
(LIMCs) were isolated from fresh PSC and PBC explants and plasmablast 
(CD19+CD27+CD38hiCD138−) and plasma cell (CD19+CD27+CD38hiCD138+) ASCs were 
enumerated by flow cytometry. We observed 45-fold fewer plasma cells in PSC explants (n = 9) 
compared to PBC samples (n = 5, p < 0.01) and 10-fold fewer IgA-, IgG- and IgM-positive 
ASCs (p < 0.05). Liver-infiltrating ASCs from PSC and PBC explants were functional and 
produced similar concentrations of IgA, IgG and IgM following 2 weeks of culture. Antibody 
production by PBC ASCs (n = 3) was disease-specific as AMA to pyruvate dehydrogenase 
complex E2 subunit (PDC-E2) was detected by immunostaining, immunoblotting and ELISA. 
Antibody profiling of PSC supernatants (n = 9) using full-length recombinant human protein 
arrays (Cambridge Protein Arrays) revealed reactivities to nucleolar protein 3 (5 / 9) and 
hematopoietic cell-specific Lyn substrate 1 (3 / 9). Array analysis of PBC supernatants (n = 3) 
detected reactivities to PDC-E2 and hexokinase 1 (3 / 3). In conclusion, we detected unique 
frequencies of liver-infiltrating ASCs in PSC and PBC and in so doing, highlight a feasible 
approach for understanding disease-relevant antibodies in PSC.
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1. Introduction 
 
Primary biliary cholangitis (formerly known as cirrhosis; PBC) and primary sclerosing 
cholangitis (PSC) are immune-mediated cholestatic liver diseases of unknown etiology. PBC is 
prototypically autoimmune with a characteristic serologic profile: anti-mitochondrial antibodies 
(AMA) to the E2 subunit of pyruvate dehydrogenase complex (PDC-E2) and anti-nuclear 
antibodies (ANA) to gp210 and sp100 are sensitive and specific diagnostic biomarkers. Other 
PBC-specific auto-antibody targets include kelch-like 12 (KLHL12) and hexokinase 1 (HK1) 
[1,2]. Although PBC and PSC are characterized by chronic inflammatory insults to the biliary 
tree with subsequent cholestasis and progressive biliary fibrosis, the nature and site of biliary 
inflammation are distinct. 
 
One area in which our understanding of the underlying disease biology has advanced 
significantly has been through genetic risk association studies [3]. For PBC and PSC, significant 
HLA and non-HLA genetic associations are evident, and whilst in essence are non-overlapping, 
confirm dominant HLA associations for both diseases [4,5]. In the case of PBC, such HLA 
associations have been used to understand the role of PDC-E2 in disease pathogenesis as patients 
who are anti-sp100 seropositive have distinct HLA profiles [6]. Similar findings relating to anti-
cyclic citrullinated antibodies have also been observed in rheumatoid arthritis (RA) [7]. In the 
setting of PSC, characteristic auto-antibodies remain to be demonstrated. There are diverse 
reports of auto-antibodies to biliary and colonic epithelial antigens, neutrophil granulocytes 
(perinuclear anti-neutrophil cytoplasmic antibodies; pANCA) and several ubiquitous self-
antigens however all of these are lacking robust validation and/or disease specificity [8]. This is 
an anomaly given the nature and strength of the genetic HLA association seen in PSC [9,10] 
	  6 
which strongly resembles archetypical autoimmune disorders such as celiac disease (CD) and 
type 1 diabetes (T1D) [11]. 
 
Previous studies assessing liver-infiltrating ASCs from PSC and PBC patients are inconclusive 
[12,13] and our general understanding of antibody-secreting B cells (ASCs) within the liver is 
limited. For example, it is unknown if the main constituents of the ASC population, namely 
short-lived plasmablasts and long-lived plasma cells, are present in unique frequencies in PSC 
and PBC liver. Such distinctions could be important for the treatment of PSC as auto-antibody 
production in PBC patients was significantly reduced upon selective plasmablast depletion using 
anti-CD20 monoclonal antibody (rituximab) [14]. Recent evidence in RA also suggests that 
plasmablasts at sites of active inflammation may act as the primary source of disease-relevant 
auto-antibodies [15,16]. Hence, differences in the relative proportions and absolute numbers of 
liver-infiltrating plasmablasts and plasma cells in PSC and PBC may influence disease-relevant 
auto-antibody concentrations. 
 
By inference to the HLA risk association studies in PSC, we therefore hypothesize that PSC has 
triggers that include a distinct repertoire of antigenic targets and associated auto-antibodies that 
are disease-specific, and potentially are more readily identified from liver. Herein we report the 
isolation of fresh PSC and PBC liver-infiltrating mononuclear cells (LIMCs) to characterize the 
plasmablast and plasma cell ASC subsets, to confirm the production of disease-relevant auto-
antibodies by PBC ASCs and to capture the auto-antibody profile of PSC ASCs using 
recombinant human protein arrays, with AMA in PBC as a methodologic control. 
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2. Methods and Materials 
 
2.1. Human liver tissue and study cohort. 
Fresh PSC and PBC liver explants were collected through the transplantation program at Queen 
Elizabeth Hospital in Birmingham, United Kingdom and were obtained with patient consent and 
in accordance with local research ethics committee approval (LREC #06-Q2702-61). Clinical 
details of the PSC and PBC study cohorts are listed in Table 1. Sample numbers (n) for each 
experiment are provided within the figure legends. 
 
2.2. Isolation of liver-infiltrating mononuclear cells (LIMCs) and enrichment for ASCs. 
PSC and PBC liver sections were cut into 1-2 mm3 pieces, thoroughly washed 3-4 times with 
PBS and resuspended in digestion media [RPMI 1640, 3% FBS, collagenase type 1A (VWR 
International)] at 37º C for 30 min. Digested tissue was mechanically homogenized using a 
Stomacher400 circulator (Seward) and washed repeatedly with PBS through 63 µm nylon filters. 
Washed tissue was discarded and the filtered cell suspension was aliquoted into 50 ml conical 
tubes and spun at 600 g for 5 min. Supernatant was discarded and cell pellets were resuspended 
and washed 3-4 times with PBS. Following the final wash, cell pellets were resuspended in PBS 
and LIMCs were isolated by density centrifugation using Lympholyte-H (Cedarlane). Collected 
LIMCs were resuspended in PBS and the total cells per gram of tissue was calculated using a 
hemocytometer (Hawksley). 
 
2.3. Antibodies and flow cytometry. 
LIMCs transferred to 96-well U-bottom plates (1 x 106 cells/well) were stained with anti-human 
CD3 FITC (BD Pharmingen; clone HIT3a), CD19 PE-eFluor610 (Biolegend; clone HIB19), 
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CD27 Brilliant Violet510 (Biolegend; clone LG.3A10), CD38 PE (eBiosciences; clone HB7), 
CD138 APC (eBioscience; clone DL-101), IgM eFluor450 (eBioscience; clone SA-DA4), IgG 
PerCP/Cy5.5 (Biolegend; clone M1310G05), IgA PE-Vio770 (Miltenyi Biotec; clone IS11-
8E10) and Zombie NIR viability dye (Biolegend). Data was acquired using a CyAn 9-colour 
flow cytometer (Beckman Coulter) and analyzed by FlowJo 8.7 (Treestar). 
 
2.4. Immunohistochemistry for CD20 and NOL3. 
Formalin-fixed paraffin-embedded PSC and PBC liver tissue was dewaxed and rehydrated with 
water after low temperature retrieval [17]. Sections were immunostained with anti-human CD20 
(ImPath; clone L26) or nucleolar protein 3 (NOL3, Sigma-Aldrich; clone ABC837), 
counterstained with haematoxylin and mounted with a glass coverslip. Tissue slides were 
scanned (ZxioScan.Z1, Zeiss) and CD20 staining was quantified by Image Processing and 
Analysis in Java (ImageJ, NIH) using a single colour threshold analysis of 10 representative 
areas of B cell infiltration near portal tracts and bile ducts. Magnification, dimensions and colour 
thresholds for each representative image area were kept identical between samples. NOL3 
staining intensity was graded as negative (-), weak (+), moderate (++) and strong (+++). Muscle 
present in the vasculature served as an internal positive control showing moderate cytoplasmic 
and strong nuclear staining. IgG controls were negative (Supplementary Figure 1). 
 
2.5. LIMC culture and IgA, IgG, IgM ELISA. 
Freshly isolated LIMCs were resuspended in culture media (RPMI 1640, 10% FBS, L-glutamine, 
1X penicillin-streptomycin) and transferred to 24-well tissue culture plates (2 x 106 cells / ml; 1 
ml total / well) and cultured in a humidified 37º C, 5% CO2 incubator. Supernatant was harvested 
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at the indicated time points and stored at −80º C for batch analysis. Supernatant IgA, IgG and 
IgM were measured by ELISA. X50 Immulon 2HB 96-well flat-bottom plates (Fisher Scientific) 
were coated with LIMC culture supernatants overnight and serial dilutions of purified IgA 
(Sigma I1010), IgG (Sigma I4506) and IgM (Sigma I8260) were used as protein standards. IgA, 
IgG and IgM was detected using primary anti-human IgA (Dako; clone F0204), IgG (University 
of Birmingham; clone AF6) or IgM (University of Birmingham; clone R10) followed by anti-
mouse or anti-rabbit HRP antibody staining (Jackson Laboratories; 715-035-151 and 111-035-
003). HRP chromogenic substrate (SurModics) was added to each well followed by stop reagent 
(SurModics). Absorbance values at 450 nm and 550 nm were measured using a 96-well plate 
reader (Bio-TEK) and final absorbance values were calculated by subtracting 450 nm and 550 
nm readings. All standards and samples were run in triplicate. 
 
2.6. Indirect immunofluorescence, immunoblotting and ELISA for AMA. 
PBC LIMC culture supernatants (day 14) were concentrated 20-fold by volume using 100K 
nominal molecular weight limit centrifugal filters (Millipore) [18] and tested for AMA using 
indirect immunofluorescence (IF), immunoblotting (IB) and ELISA. For IF staining, 
concentrated supernatants were incubated with rat stomach, liver and kidney tissue slides 
(NOVA Lite, Inova Diagnostics) for 20 mins at room temperature. Slides were washed with PBS, 
stained with fluorescent conjugate, washed again with PBS and mounted. Slides were viewed at 
20X magnification using a fluorescence microscope (Axioskop 40, Zeiss) and imaged using 
AxioVision SE64 Rel. 4.9 software (Zeiss). For IB, concentrated supernatants were loaded 
manually onto immunoblot test strips (BlueDiver Dot LI7DIV-24, D-tek) and processed 
automatically on a BlueDiver instrument (D-tek). Dried strips were visually inspected for 
staining and imaged using a Photosmart C4480 scanner (Hewlett-Packard). For AMA ELISAs, 
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AMA concentrations were measured in concentrated PBC supernatants using anti-M2-3E ELISA 
kits (EA 1622-9601 G, Euroimmun) and relative units (RU) were calculated using a negative 
control. 
 
2.7 High-density human recombinant protein microarrays. 
Auto-antibody specificities of cultured LIMC supernatants were profiled using HuProt v1 and v2 
protein arrays (Cambridge Protein Arrays). Briefly, recombinant human GST-tagged proteins 
were purified from yeast and printed on glass slides in duplicate. Slides were probed with LIMC 
culture supernatant (sample), biotinylated anti-GST antibody (positive control) or fresh culture 
media (negative control). Slides were washed and stained with fluorochrome-labeled anti-human 
IgA, IgG, IgM or streptavidin. Fluorescence intensities were measured by a plate photometer and 
analyzed by Scanarray Express software (PerkinElmer Life Sciences). 
 
For each protein, the Z-score and Interaction Score (IS) were used to determine signals of 
significance or “hits” (Supplementary Figure 2). Z-scores represent the signal of a specific 
protein relative to the signal from a negative control protein and is calculated as: Z-score = 
(Fprotein – Faverage) / SD, where Fprotein = sample fluorescence of a specific protein minus 
fluorescence of negative control protein, Faverage = mean fluorescence of total protein array 
excluding control spots and SD = standard deviation. IS is the signal relative to the staining 
intensity of the same protein using anti-GST antibody and is calculated as: IS = (HS / FGST-protein) 
x 103, where FGST-protein = fluorescence intensity of a specific protein using the anti-GST antibody. 
Hits were defined as protein targets with a Z-score ≥ 1.5, an IS ≥ 0.3, a signal-to-noise ratio 
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(S/N) > 2.5 and a SD between duplicates < 0.25. All hits adhering to the above criteria were 
verified by visual inspection. 
 
2.8. Statistical Analyses and Venn Diagram. 
Statistical analyses were performed using Prism 6 (GraphPad). Data was tested for normality 
using the D’Agostino-Pearson omnibus test and statistical significance of non-parametric data 
was calculated using an unpaired two-way Mann-Whitney. Error bars represent the interquartile 
range and were calculated as the difference between the first and third quartiles. Statistical 
differences of p < 0.05 were considered significant. Venny 2.1 (Centro Nacional de 
Biotechnologia) was used to generate the Venn diagram depicting shared auto-antibody protein 
targets in PSC and PBC samples (Figure 6B). 
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3. Results 
 
3.1. Frequencies and total numbers of liver-infiltrating B cells are decreased in PSC. 
To determine if distinct frequencies or numbers of liver-infiltrating ASCs were present in PSC 
and PBC, we quantified the overall B cell population in fresh liver explants by 
immunohistochemistry (Figure 1A). Using CD20 as a general marker of B cell infiltration [19], 
we detected significantly fewer CD20+ cells surrounding the portal tracts and bile ducts in PSC 
compared to PBC (PSC: 1.05 ± 0.18%, PBC: 4.09 ± 1.5%; median ± standard error of mean; p < 
0.01; Figure 1B). To confirm that total number of liver B cells were lower in PSC, we isolated 
LIMCs from fresh PSC and PBC explants using a combination of enzymatic digestion and 
mechanical digestion and enumerated the total B cell population (CD3–CD19+) by flow 
cytometry (Figure 1C). Consistent with our histology staining, we detected a 2.1-fold lower 
frequency of B cells within the total LIMC compartment of PSC patients (PSC: 9.9 ± 2.8%, 
PBC: 20.8 ± 7.0%, p < 0.05; Figure 1D) and 11-fold fewer B cells per gram of PSC liver tissue 
(PSC: 11,670 ± 3,428, PBC: 131,100 ± 40,460, p < 0.05; Figure 1E). Absolute numbers of 
LIMCs among PSC explants were also lower compared to PBC samples (PSC: 5.8 x 105 ± 1.5 x 
105, PBC: 9.2 x 105 ± 4.4 x 105; Supplementary Figure 3). 
 
3.2. PSC explants express lower numbers of liver-infiltrating plasma cells. 
Next, we stained PSC and PBC LIMCs with anti-human CD19, CD27, CD38 and CD138 and 
evaluated the proportion and total number of liver-infiltrating ASCs [20-22]. No significant 
differences in the overall proportion of ASCs (CD19+CD27+CD38hi) within the total B cell 
compartment of PSC and PBC samples was detected (Supplementary Figure 4) and we 
proceeded to divide ASCs into plasmablast (CD19+CD27+CD38hiCD138–) and plasma cell 
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(CD19+CD27+CD38hiCD138+) subsets using CD138 expression (Figure 2A). We observed that 
the majority of liver-infiltrating ASCs in PSC were plasmablasts (85.8 ± 4.9%) whereas PBC 
explants contained a significantly higher frequency of plasma cells (63.0 ± 5.9%, p < 0.05; 
Figure 2B) and absolute numbers of plasma cells per gram of liver tissue (PSC: 27 ± 18 cells, 
PBC: 1,227 ± 793 cells, p < 0.01; Figure 2C). 
 
3.3. Liver-infiltrating IgM-positive plasma cells are lower in PSC than PBC. 
To further characterize liver-infiltrating ASCs in PSC and PBC, plasmablasts and plasma cells 
were divided into IgA-positive, IgM-positive and IgG-positive subsets based on surface staining 
(Figure 3A) as intracellular staining of IgA, IgM and IgG identified a similar frequency of ASCs 
compared to surface staining alone (Supplementary Figure 5). In PSC, we detected a higher 
frequency of IgA-positive plasmablasts (PSC: 13.3 ± 3.6%, PBC: 3.1% ± 7.2%) and IgG-positive 
plasmablasts (PSC: 22.8 ± 5.6%, PBC: 11.3 ± 5.6%) and lower proportions of IgM-positive 
plasmablasts (PSC: 5.0 ± 2.5%, PBC: 9.6 ± 4.4%) compared to PBC (Figure 3B). PSC and PBC 
explants contained similar frequencies of IgA-positive plasma cells (PSC: 8.1 ± 2.5%, PBC: 10.2 
± 5.4%) and IgG-positive plasma cells (PSC: 19.4 ± 4.2, PBC: 21.0 ± 4.7%) however PSC 
samples contained a significantly lower proportion of IgM-positive plasma cells compared to 
PBC (PSC: 5.6 ± 1.5%, PBC: 17.6 ± 6.3%, p < 0.01; Figure 3B). In terms of absolute numbers, 
we observed slightly fewer IgA-positive and IgG-positive plasmablasts and significantly fewer 
IgM-positive plasmablasts and plasma cells in PSC explants compared to PBC (Figure 3C). IgA-
positive plasmablasts (PSC: 26 ± 35 cells, PBC: 80 ± 50 cells) and IgA-positive plasma cells 
(PSC: 6 ± 2 cells, PBC: 92 ± 315 cells, p < 0.05) per gram of liver tissue were rare in PSC and 
PBC relative to the number of IgG-positive and IgM-positive plasmablasts (IgG-positive PSC: 
168 ± 63 cells, PBC: 552 ± 265 cells; IgM-positive PSC: 28 ± 16 cells, PBC: 648 ± 229 cells, p < 
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0.05) and IgG-positive and IgM-positive plasma cells (IgG-positive PSC:  37 ± 29 cells, PBC: 
833 ± 259 cells; IgM-positive PSC: 4 ± 9 cells, PBC: 476 ± 556 cells, p < 0.05). 
 
3.4. LIMCs enriched from PSC and PBC explants contain functional ASCs. 
To determine if liver-infiltrating ASCs from end-stage PSC and PBC patients were functional, 
LIMCs from fresh explants were cultured and IgA, IgG and IgM supernatant concentrations were 
quantified by ELISA. After 1 day in culture, PSC and PBC ASCs from liver produced modest 
concentrations of antibody that continued to accumulate in supernatant for 2 weeks (Figure 4A). 
At day 14, similar concentrations of IgA (PSC: 2.5 ± 1.5 µg/ml, PBC: 2.8 ± 1.7 µg/ml), IgG 
(PSC: 3.8 ± 0.8 µg/ml, PBC: 2.5 ± 1.2 µg/ml) and IgM (PSC: 2.7 ± 1.0 µg/ml, PBC: 2.7 ± 1.3 
µg/ml) were measured in PSC and PBC supernatants (Figure 4B). We noted that liver-infiltrating 
ASCs from 2 PSC patients produced significantly higher levels of IgA at day 14 compared to the 
average PSC cohort (high IgA samples: 22.8 ± 0.2 µg/ml, average IgA samples: 2.2 ± 0.8 µg/ml; 
p < 0.01, Supplementary Figure 6). The significance of this observation is undetermined as 
antibody concentrations in LIMC cultures did not directly correlate with paired IgA, IgG and 
IgM serum titres measured at earlier time points (Supplementary Figure 7).  
 
3.5. Culture supernatant from liver-infiltrating PBC ASCs contain AMA. 
To assess if liver-infiltrating ASCs are capable of producing disease-associated auto-antibodies, 
day 14 supernatants from cultured PBC LIMCs of AMA-seropositive patients were tested for 
PDC-E2 reactivities by indirect immunofluorescence (IF). Using neat PBC supernatant (n = 3), 
AMA staining was very weak (data not shown) therefore we concentrated the supernatants 20-
fold using high-molecular weight protein filtration columns [18]. Using concentrated PBC 
supernatants, we detected weak AMA staining by IF in 1 PBC supernatant sample (PBC 1) and 
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strong AMA reactivity in 2 samples (PBC 2 and PBC 3, Figure 5A). AMA to PDC-E2 in 
concentrated PBC supernatants was quantified by ELISA (Table 2) and correlated with IF 
staining intensities as low levels of AMA to PDC-E2 was measured in PBC 1 (0.6 relative units 
[RU] /ml), intermediate levels in PBC 2 (34.21 RU/ml) and high levels in PBC 3 (256.25 RU/ml). 
Concentrated PBC supernatants (3 / 3) were AMA-positive by immunoblotting (IB) whereas 
ANA reactivities to gp120 and sp100 were absent in 3 / 3 samples (Figure 5B) which was 
expected as these samples were derived from patients who were ANA-seronegative at diagnosis. 
 
3.6. Liver-infiltrating PSC and PBC ASCs produce auto-antibodies with unique reactivities. 
Having established that PSC liver explants contain functional ASCs and liver-infiltrating ASCs 
in PBC produce disease-specific AMA, we investigated the antibody profile of cultured PSC 
LIMCs as a means of identifying possible antigenic triggers in PSC. Day 14 supernatants from 
cultured PSC LIMCs (n = 9) were screened using human full-length protein arrays covering 
~74% of the human proteome [2,23]. Using PDC-E2 reactivities in PBC supernatants as a 
methodological control, we defined positive reactivities (“hits”) as having a Z-score ≥ 1.5, an 
Interaction Score (IS) ≥ 0.3, a signal-to-noise ratio (S/N) > 2.5 and a standard deviation (SD) 
between duplicates < 0.25 (Supplementary Figure 2). At these cutoffs, reactivities to PDC-E2 
and the putative PBC antigen HK1 [1,2] were detected in 3 / 3 PBC samples cultured from 
AMA-seropositive explants (Figure 6A) and a total of 218 hits ranging between 3 to 191 per 
sample were reported (Figure 6B and Supplementary Table 1). PDC-E2 and HK1 were the only 
antibody targets shared among every PBC sample (3 / 3) and neither reactivity was detected in 
PSC supernatants (0 / 9). Antibody profiling of PSC samples revealed 98 total hits ranging from 
1 to 43 per sample. Eleven of these PSC reactivities were shared among at least 2 samples with 
auto-antibodies to nucleolar protein 3 (NOL3) detected in 5 / 9, hematopoietic cell-specific Lyn 
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substrate 1 (HCLS1) in 3 / 9, and adhesion G protein-coupled receptor A3 (ADGRA3), ATPase 
type 13A5 (ATP13A5), integrin beta-like 1 (ITGBL1), potassium channel tetramerization 
domain containing 13 (KCTD13), keratin associated protein 5-4 (KRTAP5-4), PRAME family 
member 12 (PRAMEF12), proline-rich coiled-coil 2B (PRRC2B), serine/arginine-rich splicing 
factor 1 (SFRS1) and TEA domain family member 3 (TEAD3) in 2 / 9 samples, respectively. 
None of the reactivities shared among PSC samples were reported in PBC supernatants.  
 
To determine if the auto-antibody reactivities in PSC were biological significant, we assessed if 
NOL3 auto-antibodies correlated with NOL3 protein expression in matched liver samples. In 
livers with NOL3 reactivities (PSC 4, 6 – 9), positive NOL3 expression in lymphocytes was 
detected in 3 / 5 samples and occasional staining in 2 / 5 (Supplementary Figure 1 and 
Supplementary Table 2). Patchy lymphocyte expression of NOL3 protein was also observed in 3 
/ 4 PSC livers (PSC 1 – 3) lacking NOL3 antibodies and negative in PSC 5. Lymphocyte 
expression of NOL3 was occasionally detected in 2 / 3 PBC livers (PBC 2 and PBC 3) and 
negative in PBC 1. Hepatocytes and the inflammatory interfaces of PSC and PBC livers 
irrespective of NOL3 reactivities was weak to moderate. NOL3 expression in cholangiocytes 
was strongest and mainly restricted to the cytoplasm, though some nuclear staining was noted. 
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4. Discussion 
 
For a majority of autoimmune diseases, auto-antibodies serve as markers of disease activity and 
may aid in disease diagnosis, as is the case in PBC and CD. In patients with PSC, a large number 
of auto-antibodies have been reported to date [3,8] however none of these are PSC-specific and 
epitope mapped. In an effort to better understand PSC, with the goal of improving diagnostics 
and therapeutics, we hypothesized that liver-infiltrating ASCs in PSC are disease-relevant and 
capable of producing auto-antibodies that could point to potential triggering antigens and 
mechanisms of disease. 
 
By combining enzymatic digestion and mechanical disruption of fresh end-stage explants, we 
found that PSC livers contain substantially fewer plasma cells compared to PBC but total 
plasmablast numbers were similar. Liver-infiltrating ASCs from PSC and PBC explants were 
functional and produced similar concentrations of antibodies in vitro suggesting that 
plasmablasts may be the primary source of auto-antibody production in the liver. As 
plasmablasts are indicative of recent naïve or memory B cell activation [24], these findings also 
imply that cognate antigen could be constitutively expressed and stimulating continuous 
plasmablast differentiation in end-stage disease. Similar observations have been reported in PBC 
where the majority of circulating B cells recognizing PDC-E2 exhibit a plasmablast phenotype 
(CD19+CD20-CD27+CD38hi) [25] but further work using additional ASC markers, such as 
BLIMP1 [26-28], as well as survival and proliferation studies [24] are necessary as plasma cells 
may also account for significant auto-antibody production given that plasma cell frequencies in 
PSC LIMC cultures increased after 2 weeks (Supplementary Figure 8). 
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In contrast to PBC, PSC is characteristically associated with inflammatory bowel disease (IBD) 
[4] and pro-inflammatory immune cells are recognized to traffic to the liver from inflamed gut 
[29]. Moreover it is clear that complex interactions between the intestinal mucosa and associated 
microbiota includes inflammatory responses to microbial molecules and penetration by intestinal 
microbes, both of which may be particularly relevant to disease pathogenesis in PSC-IBD 
[30,31]. Elevated IgA production in IBD has been reported in PSC [32-34] and we detected a 
higher proportion of IgA-positive plasmablasts in PSC liver and slightly higher IgA 
concentrations from PSC LIMC cultures compared to PBC. It should be noted that total numbers 
of IgA-positive ASCs in PSC samples were relatively low compared to the number of IgG-
positive and IgM-positive ASCs. This indicates that IgA responses may originate in the gut or 
appear more strongly at earlier stages of liver inflammation. Based on these results and 
observations that T cell receptor clonality is shared between gut and liver T cells [35], we 
propose that disease-relevant ASCs in PSC likely reside in both gut and liver, and may 
preferentially secrete IgA-positive auto-antibodies. 
 
In addition to immunophenotyping of ASCs, we confirmed that liver-infiltrating ASCs are a 
source of disease-specific auto-antibodies by demonstrating that culture supernatants from PBC 
LIMCs show reactivity to PDC-E2. AMA in PBC supernatants were low as IF staining increased 
substantially using concentrated samples. In 1 / 3 PBC supernatants, AMA to PDC-E2 remained 
low in concentrated supernatant as measured by IB and ELISA. As this patient was AMA-
seropositive, we suspect that disease-specific ASCs may be rare or possibly anergic in some end-
stage explants and could require additional activation by cognate antigen or cytokine cocktails to 
boost antibody production. These results support the study of end-stage explants for disease-
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specific antibodies in immune-mediated liver disorders such as PSC. We believe this approach is 
rational given that the liver is the primary site of active inflammation in PSC, and as several 
previous studies have assessed PSC serum for disease-specific antibodies [8], the use of end-
stage explants represents a novel strategy for the discovery of relevant reactivities. 
 
PSC lacks validated disease-specific antibodies [8] therefore we used recombinant human 
protein arrays to screen the antibody repertoire of liver-infiltrating ASCs in PSC, applying PDC-
E2 reactivity in PBC as a positive control. We detected 11 auto-antibody targets shared among 
PSC samples, including NOL3 (5 / 9), HCLS1 (3 / 9) and ADGRA3, ATP13A5, ITGBL1, 
KCTD13, KRTAP5-4, PRAMEF12, PRRC2B, SFRS1 and TEAD3 in 2 / 9 samples. Moderate to 
high levels of NOL3, ADGRA3, ATP13A5, KCTD13, PRAMEF12, PRRC2B and SFRS1 RNA 
and protein expression are found in liver [36,37] suggesting these proteins and associated 
pathways may have links to PSC. The correlation between NOL3 auto-antibodies and protein 
expression in cholangiocytes from the same liver is provocative given that NOL3 is an anti-
apoptotic protein with elevated expression in various cancers [38] and PSC is associated with a 
significant risk of cholangiocarcinoma [4]. Our findings require robust validation in much large 
cohorts as the majority of the reactivities detected in PSC and PBC are of unknown disease 
relevance. These auto-antibodies are most likely to be false positives but may also reflect cross-
reactivities to exogenous antigens originating from infectious pathogens or environmental 
exposures. 
 
Studies such as ours will inevitably be limited by the availability of human diseased liver 
samples and future work will require that the power and breadth of our investigations are 
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extended, both within PBC and PSC, and non-biliary related inflammatory disease, such as 
autoimmune hepatitis. Furthermore, when interpreting array data based on high density platforms 
quantifying thousands of variables, statistical validation externally is ultimately needed, 
alongside validation using single cell analyses and blood ASCs. Nevertheless, our study is 
unique and formative for future work in this field as we have identified liver-infiltrating ASCs as 
a source disease-specific auto-antibodies which could help define the molecular triggers of PSC 
and serve as early or prognostic markers of disease. 
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5. Conclusion 
 
In conclusion, using liver tissue obtained at the time of transplantation from patients with PSC 
and PBC, we have explored the hypothesis that PSC has a distinct repertoire of liver-infiltrating 
ASCs and associated auto-antibodies. In so doing, we demonstrate a difference in plasma cell 
frequency between PSC and PBC, and by identifying AMA to the PBC-specific antigen PDC-E2, 
confirm the feasibility and specificity of studying liver-infiltrating ASCs as a source of disease-
relevant antibodies in PSC. 
 
  
	  22 
Acknowledgements 
 
B.K.C is supported by the European Union Seventh Framework Programme (FP7-PEOPLE-
2013-COFUND) under grant agreement #609020 (Scientia Fellows). D.G.U would like to thank 
the Helse Sør-Øst (Project #2015024) for financial support. B.K.C, Z.S, G.M.H and E.L have 
received support from the NIHR Liver Biomedical Research Unit. We thank Matthew Taylor, 
Abid Karim and Tim Plant of the Clinical Immunology Service at the University of Birmingham 
for measuring AMA reactivity and Niamh Quann from the University of Hospitals Birmingham 
NHS Foundation Trust for clinical data. 
 
This paper presents independent research supported by the NIHR Birmingham Liver Biomedical 
Research Unit based at the University Hospitals Birmingham NHS Foundation Trust and the 
University of Birmingham. The views expressed in this publication are those of the authors and 
not necessarily those of the NHS, the NIHR or the Department of Health. 
  
	  23 
References 
 
[1] G.L. Norman, C.-Y. Yang, H.P. Ostendorff, Z. Shums, M.J. Lim, J. Wang, et al., Anti-
kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis, 
Liver International. 35 (2014) 642–651. doi:10.1111/liv.12690. 
[2] C.J. Hu, G. Song, W. Huang, G.Z. Liu, C.W. Deng, H.P. Zeng, et al., Identification of 
New Autoantigens for Primary Biliary Cirrhosis Using Human Proteome Microarrays, 
Mol. Cell Proteomics. 11 (2012) 669–680. doi:10.1074/mcp.M111.015529. 
[3] T.H. Karlsen, B.K. Chung, Genetic Risk and the Development of Autoimmune Liver 
Disease, Dig Dis. 33 Suppl 2 (2015) 13–24. doi:10.1159/000440706. 
[4] G.M. Hirschfield, T.H. Karlsen, K.D. Lindor, D.H. Adams, Primary sclerosing 
cholangitis, Lancet. 382 (2013) 1587–1599. doi:10.1016/S0140-6736(13)60096-3. 
[5] G.M. Hirschfield, M.E. Gershwin, The Immunobiology and Pathophysiology of Primary 
Biliary Cirrhosis, Annu. Rev. Pathol. Mech. Dis. 8 (2013) 303–330. 
doi:10.1146/annurev-pathol-020712-164014. 
[6] G.M. Hirschfield, X. Liu, Y. Han, I.P. Gorlov, Y. Lu, C. Xu, et al., Variants at IRF5-
TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis, Nature 
Publishing Group. 42 (2010) 655–657. doi:10.1038/ng.631. 
[7] Y. Okada, K. Kim, B. Han, N.E. Pillai, R.T.-H. Ong, W.-Y. Saw, et al., Risk for ACPA-
positive rheumatoid arthritis is driven by shared HLA amino acid polymorphisms in 
Asian and European populations, Hum. Mol. Genet. 23 (2014) 6916–6926. 
doi:10.1093/hmg/ddu387. 
[8] J.R. Hov, K.M. Boberg, T.H. Karlsen, Autoantibodies in primary sclerosing cholangitis, 
World J. Gastroenterol. 14 (2008) 3781–3791. 
	  24 
[9] E. Melum, A. Franke, C. Schramm, T.J. Weismüller, D.N. Gotthardt, F.A. Offner, et al., 
Genome-wide association analysis in primary sclerosing cholangitis identifies two non-
HLA susceptibility loci, Nature Publishing Group. 43 (2011) 17–19. 
doi:10.1038/ng.728. 
[10] J.Z. Liu, J.R. Hov, T. Folseraas, E. Ellinghaus, S.M. Rushbrook, N.T. Doncheva, et al., 
Dense genotyping of immune-related disease regions identifies nine new risk loci for 
primary sclerosing cholangitis, Nature Publishing Group. 45 (2013) 670–675. 
doi:10.1038/ng.2616. 
[11] T.H. Karlsen, A. Franke, E. Melum, A. Kaser, J.R. Hov, T. Balschun, et al., Genome-
wide association analysis in primary sclerosing cholangitis, Gastroenterology. 138 
(2010) 1102–1111. doi:10.1053/j.gastro.2009.11.046. 
[12] D. Cabibi, G. Tarantino, F. Barbaria, M. Campione, A. Craxì, V. Di Marco, Intrahepatic 
IgG/IgM plasma cells ratio helps in classifying autoimmune liver diseases, Dig Liver 
Dis. 42 (2010) 585–592. doi:10.1016/j.dld.2009.12.006. 
[13] R.K. Moreira, F. Revetta, E. Koehler, M.K. Washington, Diagnostic utility of IgG and 
IgM immunohistochemistry in autoimmune liver disease, World J. Gastroenterol. 16 
(2010) 453–457. 
[14] R.P. Myers, M.G. Swain, S.S. Lee, A.A.M. Shaheen, K.W. Burak, B-Cell Depletion 
With Rituximab in Patients With Primary Biliary Cirrhosis Refractory to 
Ursodeoxycholic Acid, Am. J. Gastroenterol. 108 (2013) 933–941. 
doi:10.1038/ajg.2013.51. 
[15] P. Suwannalai, H.U. Scherer, D. van der Woude, A. Ioan-Facsinay, C.M. Jol-van der 
Zijde, M.J.D. van Tol, et al., Anti-citrullinated protein antibodies have a low avidity 
compared with antibodies against recall antigens, Ann. Rheum. Dis. 70 (2011) 373–379. 
	  25 
doi:10.1136/ard.2010.135509. 
[16] H. Huang, C. Benoist, D. Mathis, Rituximab specifically depletes short-lived 
autoreactive plasma cells in a mouse model of inflammatory arthritis, Proceedings of the 
National Academy of Sciences. 107 (2010) 4658–4663. doi:10.1073/pnas.1001074107. 
[17] G.M. Reynolds, L.J. Billingham, L.J. Gray, J.R. Flavell, S. Najafipour, J. Crocker, et al., 
Interleukin 6 expression by Hodgkin/Reed-Sternberg cells is associated with the 
presence of 'B‘ symptoms and failure to achieve complete remission in patients with 
advanced Hodgkin’s disease, British Journal of Haematology. 118 (2002) 195–201. 
[18] K. Saha, R. Case, P.K. Wong, A simple method of concentrating monoclonal antibodies 
from culture supernatant by ultrafiltration, J. Immunol. Methods. 151 (1992) 307–308. 
[19] P. Farci, G. Diaz, Z. Chen, S. Govindarajan, A. Tice, L. Agulto, et al., B cell gene 
signature with massive intrahepatic production of antibodies to hepatitis B core antigen 
in hepatitis B virus-associated acute liver failure, Proceedings of the National Academy 
of Sciences. 107 (2010) 8766–8771. doi:10.1073/pnas.1003854107. 
[20] L. Mesin, R. Di Niro, K.M. Thompson, K.E.A. Lundin, L.M. Sollid, Long-Lived Plasma 
Cells from Human Small Intestine Biopsies Secrete Immunoglobulins for Many Weeks 
In Vitro, The Journal of Immunology. 187 (2011) 2867–2874. 
doi:10.4049/jimmunol.1003181. 
[21] D.A. Kaminski, C. Wei, Y. Qian, A.F. Rosenberg, I. Sanz, Advances in human B cell 
phenotypic profiling, Front Immunol. 3 (2012) 302. doi:10.3389/fimmu.2012.00302. 
[22] M. Cocco, S. Stephenson, M.A. Care, D. Newton, N.A. Barnes, A. Davison, et al., In 
vitro generation of long-lived human plasma cells, The Journal of Immunology. 189 
(2012) 5773–5785. doi:10.4049/jimmunol.1103720. 
[23] J.S. Jeong, L. Jiang, E. Albino, J. Marrero, H.S. Rho, J. Hu, et al., Rapid identification of 
	  26 
monospecific monoclonal antibodies using a human proteome microarray, Mol. Cell 
Proteomics. 11 (2012) O111.016253. doi:10.1074/mcp.O111.016253. 
[24] S.L. Nutt, P.D. Hodgkin, D.M. Tarlinton, L.M. Corcoran, The generation of antibody-
secreting plasma cells, Nat. Rev. Immunol. 15 (2015) 160–171. doi:10.1038/nri3795. 
[25] J. Zhang, W. Zhang, P.S.C. Leung, C.L. Bowlus, S. Dhaliwal, R.L. Coppel, et al., 
Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis, 
Hepatology. 60 (2014) 1708–1716. doi:10.1002/hep.27313. 
[26] P.G. Soro, P. Morales-A, J.A. Martínez-M, S. Morales-A, S.G. Copín, M.A. Marcos, et 
al., Differential involvement of the transcription factor Blimp-1 in T cell-independent 
and -dependent B cell differentiation to plasma cells, J. Immunol. 163 (1999) 611–617. 
[27] C. Angelin-Duclos, G. Cattoretti, K.I. Lin, K. Calame, Commitment of B lymphocytes 
to a plasma cell fate is associated with Blimp-1 expression in vivo, J. Immunol. 165 
(2000) 5462–5471. 
[28] A. Kallies, J. Hasbold, D.M. Tarlinton, W. Dietrich, L.M. Corcoran, P.D. Hodgkin, et 
al., Plasma cell ontogeny defined by quantitative changes in blimp-1 expression, J. Exp. 
Med. 200 (2004) 967–977. doi:10.1084/jem.20040973. 
[29] B. Eksteen, The Gut-Liver Axis in Primary Sclerosing Cholangitis, Clinics in Liver 
Disease. 20 (2016) 1–14. doi:10.1016/j.cld.2015.08.012. 
[30] M. Kummen, K. Holm, J.A. Anmarkrud, S. Nygård, M. Vesterhus, M.L. Høivik, et al., 
The gut microbial profile in patients with primary sclerosing cholangitis is distinct from 
patients with ulcerative colitis without biliary disease and healthy controls, Gut. (2016). 
doi:10.1136/gutjnl-2015-310500. 
[31] M.N. Quraishi, M. Sergeant, G. Kay, T. Iqbal, J. Chan, C. Constantinidou, et al., The 
gut-adherent microbiota of PSC–IBD is distinct to that of IBD, Gut. (2016) gutjnl–2016–
	  27 
311915. doi:10.1136/gutjnl-2016-311915. 
[32] M. Heydtmann, P.F. Lalor, J.A. Eksteen, S.G. Hübscher, M. Briskin, D.H. Adams, CXC 
chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating 
lymphocytes to cholangiocytes and hepatocytes within the inflamed human liver, J. 
Immunol. 174 (2005) 1055–1062. 
[33] Y.H. Oo, V. Banz, D. Kavanagh, E. Liaskou, D.R. Withers, E. Humphreys, et al., 
CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the 
inflamed liver, J. Hepatol. 57 (2012) 1044–1051. doi:10.1016/j.jhep.2012.07.008. 
[34] L. Berglin, N.K. Björkström, A. Bergquist, Primary sclerosing cholangitis is associated 
with autoreactive IgA antibodies against biliary epithelial cells, Scand. J. Gastroenterol. 
48 (2015) 719–728. doi:10.3109/00365521.2013.786131. 
[35] E. Liaskou, E.K.K. Henriksen, K. Holm, F. Kaveh, D. Hamm, J. Fear, et al., High-
throughput T-cell receptor sequencing across chronic liver diseases reveals distinct 
disease-associated repertoires, Hepatology. (2015). doi:10.1002/hep.28116. 
[36] M. Uhlén, P. Oksvold, L. Fagerberg, E. Lundberg, K. Jonasson, M. Forsberg, et al., 
Towards a knowledge-based Human Protein Atlas, Nat. Biotechnol. 28 (2010) 1248–
1250. doi:10.1038/nbt1210-1248. 
[37] M. Uhlén, L. Fagerberg, B.M. Hallström, C. Lindskog, P. Oksvold, A. Mardinoglu, et 
al., Proteomics. Tissue-based map of the human proteome, Science. 347 (2015) 
1260419. doi:10.1126/science.1260419. 
[38] M. Wang, S. Qanungo, M.T. Crow, M. Watanabe, A.-L. Nieminen, Apoptosis repressor 
with caspase recruitment domain (ARC) is expressed in cancer cells and localizes to 
nuclei, FEBS Lett. 579 (2005) 2411–2415. doi:10.1016/j.febslet.2005.03.040. 
 
TABLES 
 
Table 1. Clinical characteristics of the study cohort 
 
Clinical Characteristic 
 
PSC 
(n = 25) 
 
PBC 
(n = 13) 
 
Median age (years) 
Range 
 
51 
(17-72) 
 
53 
(32-72) 
 
Sex Distribution (M:F) 
Male 
Female 
 
14 
11 
 
1 
10 
 
Serum Auto-antibodies 
AMA-positive 
ANA-positive 
ANCA-positive 
 
  0 / 24 
12 / 24 
10 / 20 
 
  8 / 10 
  2 / 11 
2 / 9 
 
Serum Immunoglobulin (median g / L) 
IgA 
IgG 
IgM 
 
   3.9 ± 0.6 
 16.4 ± 1.6 
   1.9 ± 0.2 
 
  3.4 ± 0.8 
16.6 ± 2.2 
    3.2 ± 1.0 
 
 
Table 2. Concentration of AMA to PDC-E2 in day 14 supernatant from cultured PBC 
LIMCs. 
	
	 AMA to PDC-E2 
Sample Immunofluorescence Immunoblot ELISA (relative units/ml) 
PBC 1 + + 0.6 
PBC 2 + + / + + + + + + 34.21 
PBC 3 + + + + + + 256.26 
Figure 1. 
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SUPPLEMENTARY MATERIAL FOR REVIEW 
 
SUPPLEMENTARY TABLE LEGEND  
Supplementary Table 1. Auto-antibody targets detected in culture supernatant (day 14) of 
LIMCs enriched from PSC (n = 9) and PBC (n = 3) explants. The Z-score and Interaction Score 
(IS) is given for each antibody target with a Z-score ≥ 1.5, IS ≥ 0.3 and standard deviation (SD) 
between duplicates < 0.25. 
 
Supplementary Table 2. Immunostaining for nucleolar protein 3 (NOL3) expression in PSC (n 
= 9) and PBC (n = 3) liver explants. Cultured LIMC supernatants (day 14) from each explant 
(PSC 1 – 9 and PBC 1 – 3) were tested for NOL3 antibodies by protein array analysis (+ ; 
positive, - ; negative). NOL3 expression in lymphocytes was graded as negative, occasional or 
positive. Cholangiocyte and hepatocyte NOL3 expression was graded as weak (+), moderate 
(++) or strong (+++) based on IgG negative control and positive control staining of muscle 
present in the liver vasculature (Supplementary Figure 1). 
 
  
		 	 2	
SUPPLEMENTARY FIGURE LEGENDS 
Supplementary Figure 1. NOL3 protein expression is observed in end-stage PSC and PBC 
liver explants by immunostaining. 
PSC and PBC liver tissues were immunostained for NOL3 and counterstained with 
haematoxylin. (A) Representative NOL3 staining indicates heterogeneous cytoplasmic NOL3 
expression in hepatocytes [H] ranging from negative [A] to weak (+) intensity [B], and moderate 
(++) staining [C] at the inflammatory interfaces [II] in some cases. NOL3 expression around bile 
ducts [BD] and in cholangiocytes [D] was generally uniform and moderate to strong (++ / +++). 
Muscle surrounding the liver vasculature [V] served as internal positive controls and 
demonstrated moderate cytoplasmic and strong nuclear staining [E]. (B) Representative weak 
cytoplasmic NOL3 staining of hepatocytes [H] and strong staining of bile ducts [BD]. Positive 
NOL3 staining of lymphocytes is noticeably present and indicated with arrows. (C) 
Representative moderate to strong NOL3 staining of larger bile ducts [BD] and negative NOL3 
staining of hepatocytes [H]. (D) NOL3 staining of pre-cirrhotic regions typically showed weak 
cytoplasmic staining of hepatocytes [H] and moderate staining of bile ducts [BD] and 
cholangiocytes. 
 
Supplementary Figure 2. Workflow of protein array analysis. 
LIMCs enriched from PSC (n = 9) and PBC (n = 9) explants were cultured for 14 days and 
supernatants were assessed for auto-antibodies using the indicated workflow. Fprotein = sample 
fluorescence of specific protein, Faverage = mean fluorescence of total protein array excluding 
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control spots, SD = standard deviation, FGST-protein = fluorescence intensity of specific protein 
using anti-GST antibody. 
 
Supplementary Figure 3. Total numbers of LIMCs are reduced in PSC explants compared 
to PBC. 
LIMCs isolated using a combination of enzymatic and mechanical digestion from fresh PSC (n = 
11) and PBC explants (n = 6) were counted manually using a hemocytometer. Median number 
(#) of LIMCs per gram (g) of explanted tissue is shown and error bars represent interquartile 
range, p = 0.52. 
 
Supplementary Figure 4. PSC and PBC explants contain similar proportions of antibody-
secreting B cells (ASCs). 
LIMCs from PSC and PBC explants were stained with viability dye and anti-human CD3, CD19, 
CD27 and CD38 antibodies (or isotype controls) and analyzed by flow cytometry. (A) 
Representative flow cytometry plots indicate the proportion (%) of ASCs (CD27+CD38hi B 
cells) within the viable B cell subset of PSC and PBC explants. (B) Cumulative proportion (%) 
of ASCs within the viable B cell subset of PSC (n = 28) and PBC (n = 12) samples. 
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Supplementary Figure 5. Similar proportions of IgA+, IgG+ and IgM+ B cells are detected 
by surface and intracellular staining. 
LIMCs from PSC and PBC explants were stained with viability dye and anti-human CD3, CD19, 
CD138, IgA, IgG and IgM. Representative flow cytometry plots indicate the frequency (%) of 
viable IgA+, IgG+ and IgM+ CD138+ and CD138– B cells from a PSC (A) and PBC (B) explant 
with surface Ig staining or combined surface and intracellular (intra) Ig staining. 
 
Supplementary Figure 6. Cultured ASCs from a subset of PSC explants produce high 
concentrations of IgA. 
LIMCs containing ASCs were enriched from PSC explants (n = 21) were cultured for 14 days 
and concentrations of supernatant IgG were measured by ELISA performed in triplicate, **p < 
0.01. 
 
Supplementary Figure 7. Antibody production by cultured LIMCs does not correlate with 
serum antibody concentrations. 
LIMCs containing ASCs were enriched from PSC (n = 15) and PBC (n = 6) explants and 
cultured for 14 days. Concentrations of IgA, IgG and IgM in the supernatant of cultured PSC (A) 
and PBC (B) LIMCs were measured by ELISA performed in triplicate and matched to serum 
IgA, IgG and IgM concentrations from the same patient assessed prior to liver transplantation. 
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Supplementary Figure 8. Plasma cell frequencies increase in cultured PSC and PBC 
LIMCs. 
LIMCs enriched from PSC and PBC explants were cultured for 14 days and stained with anti-
human CD3, CD19, CD27, CD38 and CD138. (A) Representative flow cytometry plots indicate 
the frequency (%) of viable plasmablasts (PB; CD19+CD27+CD38hiCD138–) and plasma cells 
(PC; CD19+CD27+CD38hiCD138+) within the total ASC population (CD19+CD27+CD38hi). 
Positive CD138 staining was determined using a matched isotype control (not shown). (B) Dot 
plots indicate the frequency (%) of viable plasmablasts (PB) and plasma cells (PC) after 14 days 
of culture. The median frequency of the plasmablast and plasma cell subsets from PSC (n = 6 - 
10) and PBC samples (n = 3 - 4) is shown. Error bars represent interquartile range among 
samples, *p = 0.05. 
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SUPPLEMENTARY MATERIAL – TABLE 1 
  
Sample Target Gene name Z-score IS 
PSC 001 GORASP1 golgi reassembly stacking protein 1 9.6 1.7 
PSC 001 BEAN1 brain expressed associated with NEDD4, 1 2.6 0.5 
 
Sample Target Gene name Z-score IS 
PSC 002 ANKRD28 ankyrin repeat domain 28 15.1 2.7 
PSC 002 CHAC2 ChaC, cation transport regulator homolog 2 (E. coli) 6.6 1.2 
PSC 002 GAB1 GRB2 associated binding protein 1 1.7 0.3 
 
Sample Target Gene name Z-score IS 
PSC 003 SULT2B1 sulfotransferase family, cytosolic, 2B, member 1  3.2 0.5 
 
Sample Target Gene name Z-score IS 
PSC 004 LCMT1 leucine carboxyl methyltransferase 1 34.8 132.2 
PSC 004 ALG12 ALG12, alpha-1,6-mannosyltransferase 18.0 24.7 
PSC 004 RNF216P1 ring finger protein 216 pseudogene 1 17.5 93.8 
PSC 004 ZNF385B zinc finger protein 385B 12.9 58.0 
PSC 004 SDCBP syndecan binding protein (syntenin) 12.0 50.8 
PSC 004 ITGB1BP2 integrin beta 1 binding protein (melusin) 2 11.5 2.3 
PSC 004 ZNF385A zinc finger protein 385A 9.9 72.3 
PSC 004 SF3B4 splicing factor 3b, subunit 4, 49kDa 8.3 1.9 
PSC 004 TPM3 tropomyosin 3 7.5 2.1 
PSC 004 PDK2 pyruvate dehydrogenase kinase 2 6.9 9.8 
PSC 004 SNRK SNF related kinase 6.6 3.2 
PSC 004 TTN titin 6.4 1.7 
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PSC 004 RBM12 RNA binding motif protein 12 6.3 1.3 
PSC 004 ECE2 endothelin converting enzyme 2 5.8 1.7 
PSC 004 TSR3 TSR3, 20S rRNA accumulation, homolog 5.4 4.4 
PSC 004 IFI6 interferon, alpha-inducible protein 6 5.2 80.2 
PSC 004 PRRC2B proline-rich coiled-coil 2B 4.9 1.0 
PSC 004 FAM84A family with sequence similarity 84, member A 4.9 1.5 
PSC 004 FABP5 fatty acid binding protein 5 (psoriasis-associated) 4.9 1.3 
PSC 004 SFRS1 serine/arginine-rich splicing factor 1 4.8 57.0 
PSC 004 CSTF2T cleavage stimulation factor, 3' pre-RNA, subunit 2, tau variant 3.6 0.8 
PSC 004 DLG3 discs, large homolog 3 (Drosophila) 3.5 1.2 
PSC 004 AAMP angio-associated, migratory cell protein 3.3 2.6 
PSC 004 PCBP2 poly(RC) binding protein 2 3.3 0.5 
PSC 004 ARHGEF19 Rho guanine nucleotide exchange factor (GEF) 19 3.1 12.2 
PSC 004 BAK1 BCL2-antagonist/killer 1 3.1 3.3 
PSC 004 SH3GL2 SH3-domain GRB2-like 2 3.0 0.9 
PSC 004 OGFOD3 2-oxoglutarate + iron-dependent oxygenase domain 3 2.9 4.6 
PSC 004 NOL3 nucleolar protein 3 2.6 1.2 
PSC 004 HCLS1 hematopoietic cell-specific Lyn substrate 1 2.6 1.2 
PSC 004 SET SET nuclear proto-oncogene 2.5 1.5 
PSC 004 DDX58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 2.4 5.0 
PSC 004 PAF1 
PAF homolog, Paf1/RND polymerase II complex 
component 2.4 0.7 
PSC 004 MGP matrix Gla protein 2.3 3.8 
PSC 004 SPEG SPEG completx locus 2.1 4.6 
PSC 004 PPP5C protein phosphatase 5 catalytic subunit 2.1 0.7 
PSC 004 TEAD3 TEA domain transcription factor 3 2.0 1.2 
PSC 004 COPB2 coatomer protein complex subunit beta 2 1.9 2.5 
PSC 004 ATP8B5P ATPase phospholipid transporting 8B5, pseudogene 1.8 1.6 
PSC 004 CCDC155 coiled-coil domain containing 155 1.8 1.0 
PSC 004 LIMS1 LIM zinc finger domain containing 1 1.7 16.3 
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PSC 004 GTPBP6 GTP binding protein 6 1.7 11.0 
PSC 004 FIZ1 FLT3 interacting zinc finger 1 1.5 106.3 
 
Sample Target Gene name Z-score IS 
PSC 005 TAC3 tachykinin 3 42.2 87.8 
PSC 005 CLIC4 chloride intracellular channel 4 31.3 13.0 
PSC 005 PPP1R3C protein phosphatase 1, regulatory subunit 3C 28.8 71.5 
PSC 005 PRRC2B proline-rich coiled-coil 2B 12.4 2.3 
PSC 005 LSM12 LSM12 homolog 12.1 4.4 
PSC 005 TRGV9 T cell receptor gamma variable 9 6.7 15.2 
PSC 005 SFRS1 serine/arginine-rich splicing factor 1 6.6 62.4 
PSC 005 C1orf94 chromosome 1 open reading frame 94 6.0 2.5 
PSC 005 LINC01465 long intergenic non-protein coding RNA 1465 5.4 3.9 
PSC 005 LGALS13 lectin, galactoside-binding, soluble, 13 5.1 1.1 
PSC 005 BEGAIN brain enriched guanylate kinase associated 4.7 7.4 
PSC 005 PDC phosducin 4.5 1.0 
PSC 005 CEP72 centrosomal protein 72kDa 4.3 8.8 
PSC 005 CNN2 calponin 2 4.1 15.7 
PSC 005 WARS tryptophanyl-tRNA synthetase 4.0 1.2 
PSC 005 SSBP3 single stranded DNA binding protein 3 3.7 3.3 
PSC 005 TXNRD1 thioredoxin reductase 1 3.6 0.9 
PSC 005 BRF1 transcription factor TFIIIB subunit BRF1 3.4 91.1 
PSC 005 MCM6 minichromosome maintenance complex component 6 3.4 3.4 
PSC 005 SSBP2 singel stranded DNA binding protein 2 3.3 4.5 
PSC 005 TEAD3 TEA domain transcription factor 3 3.2 1.6 
PSC 005 TES testin LIM domain protein 2.8 0.6 
PSC 005 GPR31 G protein-coupled receptor 31 2.8 52.6 
PSC 005 HK3 hexokinase 3 2.7 0.8 
PSC 005 GLRX3 glutaredoxin 3 2.6 0.7 
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PSC 005 LIMD1 LIM domains containing 1 2.2 0.5 
PSC 005 MBTPS1 membrane bound transcription factor peptidase, site 1 2.0 6.0 
PSC 005 MYLK2 myosin light chai kinase 2 1.9 11.6 
PSC 005 LTC4S leukotriene C4 synthase 1.9 3.6 
PSC 005 POGZ pogo transposable element with ZNF domain 1.7 1.0 
PSC 005 MC1R melancortin 1 receptor 1.7 17.9 
PSC 005 TAPBP TAP binding protein 1.5 3.0 
 
Sample Target Gene name Z-score IS 
PSC 006 ADGRA3 adhesion G protein-coupled receptor A3 2.5 41.1 
PSC 006 NOL3 nucleolar protein 3 2.2 0.4 
PSC 006 ATP13A5 ATPase type 13A5 2.1 10.0 
PSC 006 PRAMEF12 PRAME family member 12  2.0 2.2 
PSC 006 PRKAR1B 
protein kinase cAMP-dependent type I regulatory 
subunit beta  2.0 0.3 
PSC 006 XKRY XK related, Y-linked  1.8 0.4 
PSC 006 HCLS1 hematopoietic cell-specific Lyn substrate 1  1.8 0.3 
PSC 006 KRTAP5-4 keratin associated protein 5-4 1.5 1.4 
PSC 006 ITGBL1 integrin subunit beta like 1  1.5 1.5 
 
Sample Target Gene name Z-score IS 
PSC 007 GSN gelsolin 8.1 1.4 
PSC 007 ATP13A5 ATPase type 13A5 8.0 39.4 
PSC 007 ADGRA3 adhesion G protein-coupled receptor A3 7.3 119.3 
PSC 007 KCTD13 
potassium channel tetramerization domain containing 
13 7.0 30.6 
PSC 007 PRAMEF12 PRAME family member 12 6.3 7.3 
PSC 007 TIGD1 tigger transposable element derived 1 5.8 5.7 
PSC 007 KRTAP5-4 keratin associated protein 5-4 5.2 3.6 
PSC 007 KRTAP5-2 keratin associated protein 5-2 4.0 0.8 
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PSC 007 KRTAP5-8 keratin associated protein 5-8 3.9 0.8 
PSC 007 KRTAP5-1 keratin associated protein 5-1 3.7 1.1 
PSC 007 SLC39A7 solute carrier family 39 (zinc transporter), member 7 3.2 8.6 
PSC 007 LCN15 lipocalin 15 3.0 1.1 
PSC 007 HCLS1 hematopoietic cell-specific Lyn substrate 1 3.0 0.6 
PSC 007 SOCS1 suppressor of cytokine signaling 1 2.8 1.1 
PSC 007 AKIRIN2 akirin 2 2.8 0.8 
PSC 007 FAN1 FANCD2/FANCI-associated nuclease 1 2.7 7.9 
PSC 007 KRTAP5-11 keratin associated protein 5-11 2.5 0.4 
PSC 007 NOL3 nucleolar protein 3 1.8 0.3 
PSC 007 ITGBL1 integrin subunit beta like 1  1.8 2.2 
PSC 007 PPP1R11 protein phosphatase 1 regulatory inhibitor subunit 11  1.6 0.3 
 
Sample Target Gene name Z-score IS 
PSC 008 SNAP47 synaptosome associated protein 47kDa 81.4 37.1 
PSC 008 NOL3 nucleolar protein 3 5.2 0.9 
 
Sample Target Gene name Z-score IS 
PSC 009 KCTD13 potassium channel tetramerization domain containing 13 2.9 14.2 
PSC 009 ANKHD1 ankyrin repeat and KH domain containing 1 2.8 0.5 
PSC 009 NOL3 nucleolar protein 3 2.1 0.3 
 
 
Sample Target Gene name Z-score IS 
PBC 001 HK1  hexokinase 1  7.3 8.5 
PBC 001 PDC-E2 dihydrolipoamide S-acetyltransferase 3.6 37.0 
PBC 001 CTSB cathepsin B 1.5 63.6 
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Sample Target Gene name Z-score IS 
PBC 002 HK1  hexokinase 1  11.7 2.8 
PBC 002 STARD4 StAR-related lipid transfer (START) domain containing 4 4.5 0.7 
PBC 002 HNRPA0 heterogeneous nuclear ribnucleoprotein A0 2.9 39.5 
PBC 002 RABL2B RAB, member of RAS oncogene family-like 2B 2.7 31.4 
PBC 002 IFT22 intraflagellar transport 22 2.6 2.4 
PBC 002 KRAS Kirsten rat sarcoma viral oncogene homolog 2.5 15.5 
PBC 002 LAD1 ladinin 1 2.5 1.4 
PBC 002 FGF12 fibroblast growth factor 12 2.4 21.3 
PBC 002 NXPE3 neurexophilin and PC-esterase domain family member 3 2.4 12.1 
PBC 002 MORN4 MORN repeat containing 4 2.3 11.0 
PBC 002 RRAS2 related RAS viral (r-ras) oncogene homolog 2 2.3 6.7 
PBC 002 AARS alanyl-tRNA synthetase 2.2 37.5 
PBC 002 S100A11 S100 calcium binding protein A11 2.2 4.1 
PBC 002 MS4A1 membrane spanning 4-domains A1 2.2 1.0 
PBC 002 ZNF593 zinc finger protein 593 2.2 16.6 
PBC 002 VPS4B vacuoloar protein sorting 4 homolog B 2.2 9.0 
PBC 002 CHST11 carbohydrate (chondroitin 4) sulfotransferase 11 2.2 15.9 
PBC 002 UBXN1 UBX domain protein 1 2.2 2.3 
PBC 002 TMEM14C transmembrane protein 14C 2.2 1.3 
PBC 002 NUTM2F NUT family member 2F 2.2 5.9 
PBC 002 TMEM147 transmembrane protein 147 2.2 13.1 
PBC 002 ESYT2 extended synaptotagmin protein 2 2.1 37.8 
PBC 002 LIPC lipase C, hepatic type 2.1 2.6 
PBC 002 PLBD1 phospholiapse B domain containing 1 2.1 10.6 
PBC 002 NLRP5 NLR family, pyrin domain containing 5 2.1 1.2 
PBC 002 FN3KRP fructoamine 3 kinase related protein 2.1 8.7 
PBC 002 LINC01558 long intergenic non-protein coding RNA 1558 2.0 7.8 
PBC 002 HHEX hematopoietically expresssed homeobox 2.0 0.9 
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PBC 002 RRAGD Ras related GTP binding D 2.0 8.8 
PBC 002 NELFE negative elongation factor complex member E 2.0 16.6 
PBC 002 LYPLA1 lysophospholipase I 2.0 3.4 
PBC 002 DEFB123 defensin beta 123 2.0 4.8 
PBC 002 SRI sorcin 1.9 1.2 
PBC 002 IFI16 interferon, gamma-inducible protein 16 1.9 4.8 
PBC 002 ASL argininosuccinate lyase 1.9 0.8 
PBC 002 PPP1R7 protein phosphatase 1 regulatory subunit 7 1.9 3.1 
PBC 002 SAYSD1 SAYSVFN motif domain containing 1 1.9 25.3 
PBC 002 CA12 carbonic anhydrase XII 1.9 2.4 
PBC 002 RAB35 RAB35, member RAS oncogene family 1.9 6.3 
PBC 002 TRIM39 tripartite motif containing 39 1.9 10.5 
PBC 002 BCKDK branched chain keotoacid dehydrogenase kinase 1.9 6.2 
PBC 002 LAMC2 laminin subunit gamma 2 1.9 1.0 
PBC 002 STAC3 SH3 and cysteine rich domain 3 1.9 2.7 
PBC 002 SPTLC3 serine palmitoyltransferase long chain base subunit 3 1.9 16.7 
PBC 002 PRPSAP1 
phosphoribosyl pyrophosphate synthetase-associated 
protein 1 1.9 1.2 
PBC 002 TMEM88 transmembrane protein 88 1.9 5.8 
PBC 002 RPA1 replication protein A1 1.9 8.3 
PBC 002 TESK1 testis-specific kinase 1 1.8 1.7 
PBC 002 PDC-E2 dihydrolipoamide S-acetyltransferase 1.8 3.5 
PBC 002 PLCD4 phospholipase C delta 4 1.8 1.5 
PBC 002 GPER1 G protein-coupled estrogen receptor 1 1.8 7.6 
PBC 002 GIT2 GIT ArfGAP2 1.8 2.2 
PBC 002 CADPS Ca2+ dependent secretion activator 1.8 17.2 
PBC 002 FGGY FGGY carbohydrate kinase domain containing 1.8 9.4 
PBC 002 GGH gamma-glutamyl hydrolase 1.8 14.4 
PBC 002 ECHDC3 enoyl-CoA hydratase domain containing 3 1.8 0.9 
PBC 002 TSPAN3 tetraspanin 3 1.8 49.5 
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PBC 002 PRSS36 protease, serine 36 1.8 1.6 
PBC 002 EEF1A1 eukaryotic translation elongation factor 1 alpha 1 1.8 8.4 
PBC 002 MED8 mediator complex subunit 8 1.8 3.8 
PBC 002 DDX50 DEAD-box helicase 50 1.8 7.3 
PBC 002 RRAS related RAS viral (r-ras) oncogene homolog 1.8 7.4 
PBC 002 RASL11B RAS like family 11 member B 1.8 185.9 
PBC 002 SCAND2 SCAN domain containing 2 1.8 9.1 
PBC 002 SCUBE3 
signal peptide, CUB domain and EGF like domain 
containing 3 1.8 1.9 
PBC 002 DUSP22 dual specificity phosphatase 22 1.8 4.3 
PBC 002 RNF208 ring finger protein 208 1.8 22.8 
PBC 002 CTNNA3 catenin alpha 3 1.8 6.3 
PBC 002 TOP1MT topoisomerase (DNA) I, mitochondrial 1.7 0.9 
PBC 002 GDF6 growth differentiation factor 6 1.7 3.5 
PBC 002 KCNF1 
potassium voltage-gated channel modifier subfamily 
member 1 1.7 8.5 
PBC 002 NKAP NFKB activating protein 1.7 10.3 
PBC 002 C1orf43 chromosome 1 open reading frame 43 1.7 6.0 
PBC 002 STRADB STE20-related kinase adaptor beta 1.7 4.9 
PBC 002 SOD1 superoxide dismutase 1, soluble 1.7 1.6 
PBC 002 EGFL7 EGF like domain multiple 7 1.7 17.1 
PBC 002 SERPINA10 serpin peptidase inhibitor, clade A 1.7 8.0 
PBC 002 HAP1 huntingtin-associated protein 1 1.7 3.8 
PBC 002 SH3YL1 SH3 and SYLF domain containing 1 1.7 8.2 
PBC 002 DECR2 2,4-dienoyl-CoA reductase 2, peroxisomal 1.7 1.8 
PBC 002 ACSM5 acyl-CoA synthetase medium-chain family member 5 1.7 16.0 
PBC 002 TMEM187 transmembrane protein 187 1.7 7.1 
PBC 002 PRAMEF22 PRAME family member 22 1.7 4.7 
PBC 002 DIRAS3 DIRAS family GTP binding RAS like 3 1.7 2.0 
PBC 002 FGF20 fibroblast growth factor 20 1.7 0.6 
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PBC 002 ZNF227 zinc finger protein 227 1.7 2.0 
PBC 002 WFIKKN1 
WAP, follistatin/kazal, immunoglobulin, kunitz and netrin 
domain containing 1 1.7 8.5 
PBC 002 ZNF517 zinc finger protein 517 1.7 12.0 
PBC 002 BIN3-IT1 BIN3 intronic transcript 1 1.7 6.4 
PBC 002 JTB jumping translocation breakpoint 1.7 3.2 
PBC 002 PGS1 phosphatidylglycerophosphate synthase  1.7 6.0 
PBC 002 EIF3S2 eukaryotic translation initiation factor 3 subunit I 1.7 1.8 
PBC 002 BMP15 bone morphogenetic protein 15 1.6 3.0 
PBC 002 TNK1 tyrosine kinase, non-receptor, 1 1.6 21.5 
PBC 002 RASD2 RASD family member 2 1.6 9.5 
PBC 002 SULF2 sulfatase 2 1.6 7.0 
PBC 002 DSTNP4 destrin (actin depolymerizing factor) pseudogene 4 1.6 1.2 
PBC 002 TXN2 thioredoxin 2 1.6 116.0 
PBC 002 SIGLEC10 sialic acid binding Ig like lectin 10 1.6 1.1 
PBC 002 MEOX2 mesenchyme homeobox 2 1.6 24.4 
PBC 002 RELT RELT tumor necrosis factor receptor 1.6 16.1 
PBC 002 C21orf91 chromosome 21 open reading frame 91 1.6 5.4 
PBC 002 PXYLP1 2-phosphoxylose phosphatase 1 1.6 2.9 
PBC 002 CMBL carboxymethylenebutenolidase homolog 1.6 0.8 
PBC 002 TEKT4 tektin 4 1.6 3.8 
PBC 002 ATP5O 
ATP synthase, H+ transporting, mitochondrial F1 
complex, O subunit 1.6 1.8 
PBC 002 PPBP pro-platelet basic protein 1.6 4.8 
PBC 002 PAPPA2 pappalysin 2 1.6 4.2 
PBC 002 CHRNA3 cholinergic receptor nicotinic alpha 3 subunit 1.6 8.4 
PBC 002 PSAPL1 prosaposin-like 1 1.6 23.1 
PBC 002 ALKBH8 alkB homolog 8, tRNA methyltransferase 1.6 6.0 
PBC 002 CAPN1 calpain 1 1.6 103.2 
PBC 002 RPH3AL rabphilin 3A-like 1.6 3.1 
PBC 002 EBP emopamil binding protein 1.6 19.4 
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PBC 002 FH fumarate hydratase 1.6 0.9 
PBC 002 KCNIP3 potassium voltage-gated channel interacting protein 3 1.6 1.4 
PBC 002 MTCP1 mature T-cell proliferation 1 1.6 3.6 
PBC 002 ATP5SL ATP5S-like 1.6 2.0 
PBC 002 CXCL3 C-X-C motif chemokine ligand 3 1.6 21.1 
PBC 002 KCNS3 
potassium voltage-gated channel modifier subfamily S 
member 3 1.6 5.2 
PBC 002 STMN3 stathmin 3 1.6 10.4 
PBC 002 IPPK inositol-pentakisphosphate 2-kinase 1.6 25.8 
PBC 002 MTBP MDM2 binding protein 1.6 4.5 
PBC 002 SLC30A3 solute carrier family 30 member 3 1.6 1.3 
PBC 002 CENPBD1 CENPB DNA-binding domain containing 1 1.6 6.1 
PBC 002 RTKN rhotekin 1.6 6.6 
PBC 002 AIDA axin interactor, dorsalization associated 1.6 4.2 
PBC 002 USP53 ubiquitin specific peptidase 53 1.6 12.6 
PBC 002 ZP1 zona pellucida glycoprotein 1 1.6 5.8 
PBC 002 KIAA0368 KIAA0368 1.6 8.3 
PBC 002 DCLRE1C DNA cross-link repair 1C 1.6 7.7 
PBC 002 LALBA lactalbumin alpha 1.6 4.1 
PBC 002 EMX2 empty spiracles homeobox 2 1.6 17.1 
PBC 002 HLA-E major histocompatibility complex, class I, E 1.6 7.3 
PBC 002 RTN4 reticulon 4 1.6 7.6 
PBC 002 ANGPTL3 angiopoietin like 3 1.5 7.4 
PBC 002 GP2 glycoprotein 2 1.5 1.0 
PBC 002 BTN2A2 butyrophilin subfamily 2 member A2 1.5 0.7 
PBC 002 GPR82 G protein-coupled receptor 82 1.5 27.1 
PBC 002 SHISA3 shisa family member 3 1.5 7.5 
PBC 002 TMED6 transmembrane p24 trafficking protein 6 1.5 5.6 
PBC 002 TBC1D15 TBC1 domain family member 15 1.5 5.0 
PBC 002 ZBTB9 zinc finger and BTB domain containing 9 1.5 6.6 
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PBC 002 GGT2 gamma-glutamyltransferase 2 1.5 4.8 
PBC 002 CD40 CD40 molecule 1.5 5.5 
PBC 002 TARS2 threonyl-tRNA synthetase 2, mitochondrial 1.5 14.5 
PBC 002 NTN4 netrin 4 1.5 1.3 
PBC 002 MATN3 matrilin 3 1.5 0.6 
PBC 002 LINC01547 long intergenic non-protein coding RNA 1547 1.5 3.6 
PBC 002 CNOT2 CCR4-NOT transcription complex subunit 2 1.5 17.1 
PBC 002 NMT2 N-myristoyltransferase 2 1.5 6.2 
PBC 002 RSPO4 R-spondin 4 1.5 17.9 
PBC 002 PRPS1 phosphoribosyl pyrophosphate synthetase 1 1.5 5.1 
PBC 002 SDF4 stromal cell derived factor 4 1.5 1.7 
PBC 002 HLA-DMA major histocompatibility complex, class II, DM alpha 1.5 26.7 
PBC 002 GPN3 GPN-loop GTPase 3 1.5 1.0 
PBC 002 PHF10 PHD finger protein 10 1.5 11.5 
PBC 002 WRAP73 WD repeat containing, antisense to TP73 1.5 0.5 
PBC 002 SMCP sperm mitochondria associated cysteine rich protein 1.5 1.6 
PBC 002 NPSR1 neuropeptide S receptor 1 1.5 4.4 
PBC 002 C1QTNF8 C1q and tumor necrosis factor related protein 8 1.5 1.3 
PBC 002 TNFRSF21 tumor necrosis factor receptor superfamily member 21 1.5 2.1 
PBC 002 CDK16 cyclin-dependent kinase 16 1.5 18.2 
PBC 002 PTCRA pre T-cell antigen receptor alpha 1.5 7.9 
PBC 002 CFAP45 cilia and flagella associated protein 45 1.5 12.0 
PBC 002 LBX2-AS1 LBX2 antisense RNA 1 1.5 10.3 
PBC 002 NOSTRIN nitric oxide synthase trafficking 1.5 1.7 
PBC 002 ARL8A ADP ribosylation factor like GTPase 8A 1.5 1.6 
PBC 002 FAM83F family with sequence similarity 83 member F 1.5 6.6 
PBC 002 MORC1 MORC family CW-type zinc finger 1 1.5 5.9 
PBC 002 PLD4 phospholipase D family member 4 1.5 4.8 
PBC 002 DLL1 delta-like 1 1.5 4.2 
PBC 002 LTB4R leukotriene B4 receptor 1.5 5.3 
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PBC 002 ARL4D ADP ribosylation factor like GTPase 4D 1.5 38.0 
PBC 002 PDK1 pyruvate dehydrogenase kinase 1 1.5 0.5 
PBC 002 MAPK1 mitogen-activated protein kinase 1 1.5 1.1 
PBC 002 JPH3 junctophilin 3 1.5 11.6 
PBC 002 SFTPA1 surfactant protein A1 1.5 7.8 
PBC 002 CCDC173 coiled-coil domain containing 173 1.5 1.9 
PBC 002 CAPN2 calpain 2 1.5 0.6 
PBC 002 MORN1 MORN repeat containing 1 1.5 10.6 
PBC 002 SERPINA11 
serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 11 1.5 16.7 
PBC 002 DUSP8 dual specificity phosphatase 8 1.5 4.9 
PBC 002 BTBD2 BTB domain containing 2 1.5 3.2 
PBC 002 MINK1 misshapen-like kinase 1 1.5 9.7 
PBC 002 RGS13 regulator of G-protein signaling 13 1.5 84.3 
PBC 002 RPL10L ribosomal protein L10 like 1.5 17.5 
PBC 002 PSTK phosphoseryl-tRNA kinase 1.5 20.8 
PBC 002 RPL18 ribosomal protein L18 1.5 2.0 
PBC 002 CFP complement factor properdin 1.5 6.2 
PBC 002 MLLT10 
myeloid/lymphoid or mixed-lineage leukemia; 
translocated to, 10 1.5 1.3 
 
Sample Target Gene name Z-score IS 
PBC 003 HK1 hexokinase 1 20.7 3.6 
PBC 003 NXN nucleoredoxin 10.5 1.9 
PBC 003 GPD1 glycerol-3-phosphate dehydrogenase 1 8.4 1.4 
PBC 003 SPRR1A small proline rich protein 1A 7.8 1.3 
PBC 003 SPRR3 small proline rich protein 3 6.3 1.1 
PBC 003 ECE2 endothelin converting enzyme 2 5.4 0.9 
PBC 003 PPP1R11 protein phosphatase 1 regulatory inhibitor subunit 11 4.6 0.8 
PBC 003 CUTA cutA divalent cation tolerance homolog (E. coli) 4.1 0.7 
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PBC 003 SULT2A1 sulfotransferase family 2A member 1 3.7 0.6 
PBC 003 TMOD1 tropomodulin 1 3.6 0.6 
PBC 003 DIABLO diablo, IAP-binding mitochondrial protein 3.6 0.6 
PBC 003 APITD1 apoptosis-inducing, TAF9-like domain 1  3.6 0.6 
PBC 003 CTBP1 C-terminal binding protein 1 3.3 0.6 
PBC 003 NGB neuroglobin 2.9 0.5 
PBC 003 GATSL2 GATS protein-like 2 2.7 0.5 
PBC 003 KRTAP17-1 keratin associated protein 17-1 2.6 0.5 
PBC 003 FOXA3 forkhead box A3 2.6 1.5 
PBC 003 PDHB pyruvate dehydrogenase (lipoamide) beta 2.4 1.6 
PBC 003 RAB11A RAB11A, member RAS oncogene family 2.4 0.4 
PBC 003 ITM2C integral membrane protein 2C 2.3 33.3 
PBC 003 PQBP1 polyglutamine binding protein 1 2.2 0.4 
PBC 003 GGA1 
golgi-associated, gamma adaptin ear containing, ARF 
binding protein 1 2.1 0.4 
PBC 003 RLBP1 retinaldehyde binding protein 1 2.0 0.3 
PBC 003 ZNF696 zinc finger protein 696 2.0 0.4 
PBC 003 PSMA4 proteasome subunit alpha 4  1.9 0.3 
PBC 003 CDKN2C cyclin-dependent kinase inhibitor 2C  1.9 0.3 
PBC 003 DNAJC12 DnaJ heat shock protein family (Hsp40) member C12  1.8 0.3 
PBC 003 BEX5 brain expressed X-linked 5 1.8 0.3 
PBC 003 BCL2L11 BCL2 like 11  1.8 0.3 
PBC 003 MAPK1IP1L 
mitogen-activated protein kinase 1 interacting protein 1-
like 1.6 0.3 
PBC 003 PSMB6 proteasome subunit beta 6 1.6 0.3 
PBC 003 PDC-E2 dihydrolipoamide S-acetyltransferase  1.5 3.7 
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SUPPLEMENTARY MATERIAL – TABLE 2 
 
  
	  Immunostaining for nucleolar protein 3 (NOL3) 
Sample NOL3 antibodies lymphocytes cholangiocytes hepatocytes 
PSC 1 - occasional ++ / +++ + 
PSC 2 - occasional ++ + 
PSC 3 - occasional ++ / +++ + / ++ 
PSC 4 + occasional ++ + 
PSC 5 - negative + / ++ + 
PSC 6 + occasional ++ / +++ + / ++ 
PSC 7 + positive ++ / +++ + / ++ 
PSC 8 + positive ++ + 
PSC 9 + positive ++ + 
PBC 1 - negative + / ++ + 
PBC 2 - occasional + + 
PBC 3 - occasional + + 
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SUPPLEMENTARY MATERIAL – FIGURE 1 
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SUPPLEMENTARY MATERIAL – FIGURE 2 
 
 
 
 
 
SUPPLEMENTARY MATERIAL – FIGURE 3 
 
GST staining 
High resolution data acquisition, raw data normalization and background correction 
Secondary reagent 
control Sample incubation 
Calculation of: 
Fprotein 
Faverage 
SD 
Positive “Hits” 
(fulfilling HS, IS and SD thresholds)  
Calculation of 
Interaction Score (IS): 
(HS/FGST-protein)*10000 
Calculation of: 
FGST-protein 
Calculation of 
Z-score: 
(Fprotein – Faverage / SD 
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SUPPLEMENTARY MATERIAL – FIGURE 4 
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SUPPLEMENTARY MATERIAL – FIGURE 5 
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SUPPLEMENTARY MATERIAL – FIGURE 6 
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SUPPLEMENTARY MATERIAL – FIGURE 7 
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SUPPLEMENTARY MATERIAL – FIGURE 8 
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